Irish pharmaceutical group Alltracel today announced a pre-tax loss of €860,738 for the six months to June.
The company said turnover was €350,053 compared with €601,658 for the year December. Gross margins improved to 33 per cent for the first half from 31 per cent in 2001 as a whole.
The company, which floated on the London stock exchange in June of 2001, specialises in developing products which stop wounds bleeding.
It said four of its US marketing partners have applied to the US Food and Drug Administration (FDA) for approval of medical devices featuring Alltracel's "stops bleeding" technology m*doc.
READ MORE
The company said it expects the first of these FDA approvals in the second half of this year.